R&D | April 12, 2026
Touchlight and SVF partner to advance next-gen Hepatitis B/D vaccine development
The company says the platform offers improved manufacturability and functional advantages
The company says the platform offers improved manufacturability and functional advantages
The event also featured discussions on emerging trends in joint replacement surgery
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
The nationwide campaign, running from April 9–23 highlights the first 1,000 days, nutrition, responsive caregiving and play-based learning as critical pillars for children
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
20 among them to receive $20,000 grants
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
